Cristy Ku, None;
Mariana da Palma, None;
Austin Igelman, None;
Andreas Lauer, None;
Steven Bailey, None;
Jacque Duncan, Acucela (F), AGTC (C), Allergan (F), Editas Medicine (C), Neurotech USA (F), NightstaRx Limited (F), ProQRTherapeutics (C), Second Sight Medical Products (F), SparingVision (C), Spark Therapeutics (C);
Paul Yang, Adverum (C), AGTC (C), Nanoscope Therapeutics (C), NIH (F);
Mark Pennesi, Adverum (C), AGTC (F), AGTC (C), Astellas Pharmaceuticals (C), Atsena (C), Biogen (F), Biogen (C), Blue Rock (C), DTx (C), Editas (F), Endogena (C), Foundation Fighting Blindness (F), Gensight (C), Horama (C), IVERIC (C), Nacuity Pharmaceuticals (C), Nayan (C), Novartis (C), ProQR Therapeutics (C), ProQR Therapeutics (F), RegenexBio (C), Roche (C), Sanofi (F), Sanofi (C), Viewpoint Therapeutics (C)